ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2261

A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis

Zsolt Kulcsar1, Lena Saleh2, Shravani Gangidi3 and Poonam Khadka4, 1Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, 2The Dartmouth Institute For Healthcare Policy and Clinical Practice, Lebanon, NH, 3The Dartmouth Institute For Healthcare Policy and Clinical Practice, lebanon, NH, 4Endocrinology, Dartmouth Hitchcock Medical Center, lebanon, NH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Bisphosphonates, menopause, osteoporosis and parathyroid hormone

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose:
Bisphosphonates are currently the drug of choice for treatment of osteoporosis. While anabolic agents like parathyroid hormone (PTH) have shown greater improvements in bone mineral density (BMD) in severe osteoporosis, their use is limited to a maximum of 2 years due to risk of osteosarcoma with rapid loss of gained BMD after cessation of treatment. Given the limits of both agents, we want to assess the effects of PTH and bisphosphonate combination therapy versus monotherapy with either agent on BMD in patients with osteoporosis.

Methods:
We searched MEDLINE, the Cochrane Library, and ClinicalTrials.gov from inception to October 2013. We also reviewed reference lists of included studies and searched the abstracts of the last four years of relevant scientific meetings. We included randomized trials comparing combination therapy with bisphosphonate and PTH versus monotherapy with either agent in men and post-menopausal women with osteoporosis followed for at least 3 months. Studies had to report mean change in BMD as measured by dual-energy X-ray absorptiometry (DEXA) at either the total hip or lumbar spine. Data collection and analysis was done by at least two reviewers independently collected data from each study using a standardized form. We used random effects models to calculate pooled weighted mean differences (WMD) and relative risks (RR).

Results:

Of 332 studies identified, six met all inclusion criteria. Combination therapy led to small increases in % change in BMD at the total hip compared to PTH alone (WMD 0.38, 95% CI -1.41 to 2.18, I2=80%, 5 studies) and bisphosphonate alone (WMD 0.15, 95% CI -0.82 to 1.12, I2=38%, 5 studies). Similarly, combination therapy resulted in larger increases in % change in BMD at the spine compared to bisphosphonate alone (WMD 3.65, 95% CI 1.82 to 5.47, I2=67%, 5 studies), however PTH alone was superior to combination therapy at the lumbar spine (WMD -0.54, 95% CI -2.15 to 1.07, I2=46%, 5 studies). Based on 6 studies, there was a significant risk in developing hypercalcemia with combination therapy compared to monotherapy (11.83% vs. 7.04%, RR 1.68, 95% CI 1.18 to 2.41).

Conclusion:
Combination therapy with PTH and bisphosphonates leads to greater improvements in BMD only at the lumbar spine compared to bisphosphonate therapy alone, however at the cost of increased risk of hypercalcemia.


Disclosure:

Z. Kulcsar,
None;

L. Saleh,
None;

S. Gangidi,
None;

P. Khadka,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-meta-anlaysis-of-bisphosphonate-and-parathyroid-hormone-pth-use-in-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.